Compare Stocks: VSTM, ZBIO, INVA, and MNKD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INVA Innoviva	$21.16 -0.3%	$22.22	$16.52 ▼ $25.15	$1.56B	0.34	741,043 shs	508,588 shs
MNKD MannKind	$4.08 -0.8%	$3.88	$2.23 ▼ $6.51	$1.27B	1.09	5.50 million shs	5,584 shs
VSTM Verastem	$6.01 -1.6%	$4.66	$3.43 ▼ $11.24	$536.89M	0.29	2.25 million shs	1,373 shs
ZBIO Zenas BioPharma	$32.66 +1.2%	$24.06	$13.50 ▼ $44.60	$2.06B	-0.96	854,007 shs	1,876 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INVA Innoviva	-1.94%	+0.09%	-6.56%	-7.70%	+15.14%
MNKD MannKind	+6.75%	+5.66%	-3.52%	+45.23%	+6.20%
VSTM Verastem	+1.50%	-1.29%	+59.69%	+11.72%	-2.09%
ZBIO Zenas BioPharma	+3.80%	+4.13%	+27.15%	+67.03%	+104.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INVA Innoviva	$21.16 -0.3%	$22.22	$16.52 ▼ $25.15	$1.56B	0.34	741,043 shs	508,588 shs
MNKD MannKind	$4.08 -0.8%	$3.88	$2.23 ▼ $6.51	$1.27B	1.09	5.50 million shs	5,584 shs
VSTM Verastem	$6.01 -1.6%	$4.66	$3.43 ▼ $11.24	$536.89M	0.29	2.25 million shs	1,373 shs
ZBIO Zenas BioPharma	$32.66 +1.2%	$24.06	$13.50 ▼ $44.60	$2.06B	-0.96	854,007 shs	1,876 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INVA Innoviva	-1.94%	+0.09%	-6.56%	-7.70%	+15.14%
MNKD MannKind	+6.75%	+5.66%	-3.52%	+45.23%	+6.20%
VSTM Verastem	+1.50%	-1.29%	+59.69%	+11.72%	-2.09%
ZBIO Zenas BioPharma	+3.80%	+4.13%	+27.15%	+67.03%	+104.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INVA Innoviva	2.57	Moderate Buy	$36.20	70.59% Upside
MNKD MannKind	2.50	Moderate Buy	$9.34	127.34% Upside
VSTM Verastem	2.91	Moderate Buy	$14.40	136.07% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$44.29	37.23% Upside

Current Analyst Ratings Breakdown

Latest VSTM, ZBIO, INVA, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $14.00
7/23/2026	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	MNKD MannKind	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/7/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$15.00 ➝ $14.00
7/7/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/2/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
6/24/2026	INVA Innoviva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
6/24/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
6/24/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INVA Innoviva	$420.69M	3.72	$4.93 per share	4.30	$15.71 per share	1.35
MNKD MannKind	$348.97M	3.64	$0.07 per share	62.22	($0.17) per share	-24.18
VSTM Verastem	$30.91M	17.34	N/A	N/A	$0.74 per share	8.24
ZBIO Zenas BioPharma	$10M	203.72	N/A	N/A	$4.51 per share	7.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INVA Innoviva	$271.17M	$6.01	3.53	9.87	N/A	119.89%	33.33%	22.67%	8/5/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.07	N/A	41.10	N/A	-6.63%	-11.21%	-3.92%	8/5/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.70	N/A	N/A	N/A	-391.17%	-486.40%	-91.56%	8/6/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.47	N/A	N/A	N/A	N/A	-99.99%	-58.06%	8/11/2026 (Estimated)

Latest VSTM, ZBIO, INVA, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ZBIO Zenas BioPharma	-$0.89	N/A	N/A	N/A	$15.00 million	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.46	N/A	N/A	N/A	$22.88 million	N/A
8/5/2026	Q2 2026	INVA Innoviva	$0.4360	N/A	N/A	N/A	$110.99 million	N/A
8/5/2026	Q2 2026	MNKD MannKind	-$0.02	N/A	N/A	N/A	$108.80 million	N/A
5/13/2026	Q1 2026	ZBIO Zenas BioPharma	-$1.4742	-$1.46	+$0.0142	-$1.46	$25.00 million	N/A
5/6/2026	Q1 2026	INVA Innoviva	$0.43	$0.44	+$0.01	$2.22	$101.57 million	$97.99 million
5/6/2026	Q1 2026	MNKD MannKind	-$0.02	-$0.05	-$0.03	-$0.05	$105.38 million	$90.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INVA Innoviva	0.19	21.13	20.07
MNKD MannKind	N/A	1.87	1.50
VSTM Verastem	0.89	3.04	3.00
ZBIO Zenas BioPharma	1.04	11.94	11.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INVA Innoviva	99.12%
MNKD MannKind	49.55%
VSTM Verastem	88.37%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
INVA Innoviva	2.01%
MNKD MannKind	2.60%
VSTM Verastem	1.94%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INVA Innoviva	100	73.81 million	72.33 million	Optionable
MNKD MannKind	400	308.95 million	300.92 million	Optionable
VSTM Verastem	50	87.87 million	86.17 million	Optionable
ZBIO Zenas BioPharma	N/A	63.13 million	49.24 million	N/A

VSTM, ZBIO, INVA, and MNKD Headlines

Recent News About These Companies

Comparing Zenas BioPharma (NASDAQ:ZBIO) & Arcturus Therapeutics (NASDAQ:ARCT)

July 30 at 2:28 AM | americanbankingnews.com

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts

July 29 at 4:28 AM | marketbeat.com

Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

July 28 at 6:23 AM | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC

July 24, 2026 | marketbeat.com

SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO

July 24, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO

July 22, 2026 | marketbeat.com

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

July 17, 2026 | quiverquant.comQ

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026 | globenewswire.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?

July 17, 2026 | marketbeat.com

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

July 14, 2026 | seekingalpha.com

Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

July 11, 2026 | finance.yahoo.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Down 8% - Here's Why

July 10, 2026 | marketbeat.com

Zenas BioPharma Inc ZBIO

June 27, 2026 | morningstar.comM

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

June 24, 2026 | theglobeandmail.com

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

June 21, 2026 | fool.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2026 | globenewswire.com

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

June 11, 2026 | globenewswire.com

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...

June 2, 2026 | finance.yahoo.com

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

June 2, 2026 | globenewswire.com

A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness

June 1, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, ZBIO, INVA, and MNKD Company Descriptions

Innoviva NASDAQ:INVA

$21.16 -0.07 (-0.31%)

As of 09:31 AM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

MannKind NASDAQ:MNKD

$4.08 -0.03 (-0.83%)

As of 09:31 AM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Verastem NASDAQ:VSTM

$6.00 -0.10 (-1.56%)

As of 09:31 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$32.66 +0.39 (+1.20%)

As of 09:31 AM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, ZBIO, INVA, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, ZBIO, INVA, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, ZBIO, INVA, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, ZBIO, INVA, and MNKD Company Descriptions

Innoviva NASDAQ:INVA

MannKind NASDAQ:MNKD

Verastem NASDAQ:VSTM

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, ZBIO, INVA, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, ZBIO, INVA, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, ZBIO, INVA, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, ZBIO, INVA, and MNKD Company Descriptions

Innoviva NASDAQ:INVA

MannKind NASDAQ:MNKD

Verastem NASDAQ:VSTM

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools